



INVESTIGATION ON THE EFFECT OF SOME ANTIPARASITIC AND ANTIBIOTICS ON THE IMMUNE RESPONSE OF DOGS TO RABIES VACCINE

Mohamed I. Emam^a, El-Sayed M. Galila^b, Abdelfatah M. Abdelfatah^b, Abdelmonem M. Mustafa, Faysal K. Hamouda^b and Mohamed Khodeir^c

^a police academy, ^b Faculty of Veterinary Medicine, Benha University, veterinary Serum and Vaccine Research Institute, Abbassia, Cairo.

ABSTRACT

The present study was planned to determine the effect of some familiar drugs used for dog treatment including antibiotic as E-Mox®; antiparasitic drugs as levamisol® and Yomesan® on the immune response of dogs to the locally produced inactivated rabies vaccine, through the application of SNT and indirect solid phase ELISA. SNT revealed that specific rabies neutralizing antibodies stated from the first week post vaccination in vaccinated all puppy groups then increased gradually to reach their peak by the 4th week later then still unchanged till the 12th month. It was visible that the highest levels of serum neutralizing rabies antibodies were determined in puppies received Levamisol® reached 256. Other treated puppy groups did not show significant differences between them. The vaccinated untreated group and Yomesan® treated group were reached 32 meanwhile the treated group with E-Mox® which showed the lowest antibody titer was 16. It was clear that the results of ELISA were in parallel to those of SNT showing that the highest levels of rabies ELISA antibodies were determined in puppies received Levamisol®. Other treated groups did not show significant differences. The results of the vaccinated un-treated group and Yomesan® treated group were similar. While the treated group with E-Mox® showed the lowest antibody titer. Similarly, the serum proteins showed elevation in the Levamisol® treated group. On the other hand the E-Mox® treated group showed the lowest serum proteins level. There were no significance differences the level of the serum protein among the other groups.

Key Words: Dog, Antiparasitic, Antibiotic, Rabies vaccine, SNT

(BVMJ 24(2): 165 -172, 2013)

1. INTRODUCTION

Rabies virus is the type species of the Lyssavirus genus, in the family Rhabdoviridae, order Mononegavirales, Lyssaviruses have helical symmetry, with a length of about 180 nm and a cross-sectional diameter of about 75 nm [1]. From the point of entry, the virus is neurotropic, traveling quickly along the neural pathways into the central nervous system (CNS), and then further into other organs [2]. The salivary glands

receive high concentrations of the virus thus allowing further transmission. Any warm-blooded animal (including humans) may become infected with the rabies virus and develop symptoms [3]. Infected bats, [4] monkeys, raccoons, foxes, skunks, cattle, wolves, coyotes, dogs, mongoose (normally yellow mongoose) [5] or cats present the greatest risk to humans. Rabies may also spread through exposure to infected domestic farm animals, groundhogs, weasels, bears and other wild

carnivores. Small rodents such as squirrels, hamsters, guinea pigs, gerbils, chipmunks, rats, and mice and lagomorphs like rabbits and hares are almost never found to be infected with rabies and are not known to transmit rabies to humans [6].

The virus is usually present in the nerves and saliva of a symptomatic rabid animal [7]. The route of infection is usually, but not always, by a bite. In many cases the infected animal is exceptionally aggressive, may attack without provocation, and exhibits otherwise uncharacteristic behavior [8]. There are an estimated 55,000 human deaths annually from rabies worldwide, with about 31,000 in Asia, and 24,000 in Africa [9]. In these countries the virus is primarily transmitted through canines (feral dogs and other wild canine species). Recent reports suggest that wild rabid dogs are roaming the streets.

It was reported that, rabies is enzootic in jackals and common in dogs [10] and it was concluded that dogs and wolves are the primary vector animal for transmission of rabies to cattle in the Middle East [11].

The aim of this work was directed to investigate the effect of some drugs on the immune status of rabies vaccinated dogs.

2. MATERIALS AND METHODS

2.1. Dogs:

Twenty five native breed young puppies of 3 months age were used in the present study and all of them were found to be free from rabies antibodies as screened by serum neutralization test.

2.2. Rabies virus:

Cell culture adapted ERA strain of rabies virus was kindly supplied by the Department of Pet Animal Vaccine Research; Veterinary Serum and Vaccine Research Institute, Abassia, Cairo. It was supplied in a lyophilized form with a titer of 103.5 TCID₅₀ / ml. This virus was used in serum neutralization test and for preparation of rabies antigen for ELISA.

2.3. Rabies vaccine:

Inactivated cell culture rabies vaccine was obtained from Veterinary Serum and Vaccine Research Institute, Abassia, Cairo. It was used for vaccination of experimental puppies.

2.4. Drugs:

2.4.1. E-Mox®

It is a broad spectrum antibiotic composed of 250 mg amoxicillin sodium injected intramuscularly every 8 hours from first day.

2.4.2. Yomesan®:

It is composed of 0.5g nicosamide /tablet and acts by direct contact with the tapeworm causing necrosis of the head and adjoining segments and thus the worm loses its hold and it's eliminated intact or in pieces with feces. One tablet was grind and giving in liquid after breakfast for 7 days from first day.

2.4.3. Levamisol®:

It was supplied by Bayer, Leverkusen, Germany and used at the dose of 0.7ml/ kg body weight injected subcutaneous as anthelmintic drug from first day.

2.5. Cell culture:

Baby hamster kidney cell line (BHK-21) established by (12) was used in serum neutralization test.

2.6. Anti-dog immunoglobulin conjugated with horse radish peroxidase

Anti-dog immunoglobulin [IgG whole molecule] conjugated with peroxidase [Horse Radish Peroxidase enzyme (HRP)] was obtained from Sigma chemical company(USA) and treated before use by double dilution to cover the expected range and the suitable dilution was selected by using P.B.S with bovine albumin and tween 20 which gives suitable color where that titer was 1:10,000.

2.7. Kits of serum proteins

Biocan Laboratory Reagents (Germany) were used to estimate total serum protein and serum albumin in sera of experimental dogs.

2.8. Experimental vaccination of puppies

Twenty five puppies were divided into 5 groups (5 puppies/ group) as follow:

Group-1 was treated with E-Mox 250mg/8hours injected intramuscularly for 5 days. Rabies vaccine was inoculated on the first day of E-Mox treatment using 2ml injected subcutaneous.

Group-2 was vaccinated with rabies vaccine on the first day of the puppy's treatment with Yomesan using one tablet daily for 7 days.

Group-3 was treated with levamisole at the dose of 0.7ml/kg body weight injected subcutaneous in each puppy vaccinated with rabies vaccine.

Group-4 was vaccinated with rabies vaccine without any treatment.

Group-5 was kept without vaccination and without treatment.

All puppy groups were housed under hygienic measures in separate kennels receiving balanced diet and adequate water.

2.9. Sampling

Blood samples were obtained from the experimental puppies through the jugular vein puncture under complete aseptic conditions according to [13].

2.10. Serum Neutralization test (SNT)

SNT was carried out using the micro technique according to [14].

2.11. Indirect ELISA

The indirect method of ELISA was for quantitative determination of rabies antibodies according to [15] and [16].

3. RESULTS

Rabies antibodies were followed up in the sera of all experimental puppy groups through the application SNT and indirect solid phase ELISA. SNT revealed that vaccination of puppies with the inactivated cell culture rabies vaccine resulted in induction of neutralizing antibodies from the first week post vaccination in all puppy groups increased gradually to reach their

peak by the 4th week later then still unchanged till the 12th month (table 1). It was visible that the highest levels of serum neutralizing rabies antibodies were determined in puppies received Levamisole (256). Other treated puppy groups did not show significant differences between them and the vaccinated un-treated group and Yomesan treated group (32) except the treated group with E-Mox which showed the lowest antibody titer (16).

In addition, it was clear the results of ELISA were parallel to those of SNT showing that the highest levels of rabies ELISA antibodies were determined in puppies received Levamisole (2.91), Other treated puppy groups did not show significant differences between them and the vaccinated un-treated (2.5) group and Yomesan treated group (2.3) except the treated group with E-Mox which showed the lowest antibody titer (1.5) as tabulated in table (2).

It was noticed that the highest levels of serum proteins were determined in puppies received Levamisole (8.87 ± 0.25 ; 1.9 ± 0.07 & 6.7 ± 0.22 g/dl for total protein; albumin and globulin respectively). Other treated puppy groups did not show significant differences between them and the vaccinated un-treated group and Yomesan treated group (8.3 ± 0.55 ; 1.98 ± 0.07 & 6.32 ± 0.33 g/dl and 7.78 ± 0.14 ; 1.3 ± 1.1 & 5.9 ± 0.9 g/dl in untreated and puppies received Yomesan for total protein; albumin and globulin respectively) except the treated group with E-Mox which showed the lowest levels (6.9 ± 1.1 ; 2.5 ± 0.04 & 4.4 ± 0.30 for total protein; albumin and globulin respectively) as tabulated in table (3).

4. DISCUSSION

Dogs may come suffering from a disease caused by different infections needed rapid treatment using different drugs of different

Table 1. Rabies serum neutralizing antibody titers in vaccinated puppies

Periods post vaccination	Mean rabies SNT titer*				
	E-Mox®	Yomesan®	Levamisol®	Rabies vaccine	Control
1W**	2	2	16	4	0
2W	4	8	32	8	0
3W	16	8	64	16	0
4W	16	16	256	32	0
2M***	16	32	256	32	0
4MP	16	32	256	32	0
6M	16	32	256	32	0
8M	16	32	256	32	0
10M	16	32	256	32	0
12M	16	32	256	32	0

*Rabies antibody titer: the reciprocal of the final serum dilution which neutralized and inhibited the CPE of 100 TCID₅₀ of rabies virus. **WPV: week post vaccination. ***MPV= month post vaccination.

Table 2: Rabies ELISA antibody titers in vaccinated puppies

Periods post vaccination	Mean ELISA antibody titer (log 10/ml)				
	E-Mox®	Yomesan®	Levamisol®	Rabies vaccine	Control
1W*	0.80	1.50	2.37	1.69	0.24
2W	0.94	2.00	2.84	2.10	0.38
3W	0.96	2.10	2.86	2.30	0.70
4W	1.50	2.30	2.91	2.50	0.30
2M**	1.49	2.30	2.90	2.52	0.25
4M	1.50	2.31	2.92	2.50	0.44
6M	1.52	2.30	2.92	2.50	0.32
8M	1.50	2.28	2.93	2.51	0.44
10M	1.49	2.29	2.91	2.53	0.36
12M	1.49	2.30	2.89	2.54	0.23

*WPV= week post vaccination. **MPV= month post vaccination

Table 3: Serum protein levels in treated vaccinated puppies

Drug	Serum proteins (gm/dl) on weeks post treatment								
	Total serum protein			Serum albumin			Serum globulin		
	1W*	2W	3W	1W	2W	3W	1W	2W	3W
E-Mox®	6.4	6.5	6.9	2.9	2.89	2.5	3.5	3.75	4.4
	±1.1	±0.4	±0.3	±0.15	±0.09	±0.09	±0.90	±0.45	±0.30
Yomesan®	7.2	7.5	7.98	1.9	1.6	1.3	5.3	5.6	5.9
	±0.23	±0.22	±0.14	±0.8	±0.11	±1.1	±0.22	±0.33	±0.09
Levamisol®	7.9	8.1	8.87	2.1	1.9	1.5	5.0	5.99	6.7
	±0.1	±0.12	±0.25	±0.7	±0.15	±0.45	±0.0	±1.1	±0.22
Rabies vaccine	7.45	7.8	8.30	2.5	2.01	1.98	4.95	5.79	6.32
	±0.33	±0.45	±0.55	±0.15	±0.02	±0.07	±0.49	±0.59	±0.33
Control	6.1±0.15			3.1±0.32			2.5±0.07		

*W: week post treatment.

actions and accordingly the present work was planned to investigate the effect of some antibiotics as E-Mox®; antiparasitic drugs as levamisol® and Yomesan® on the immune response of dogs to the locally produced inactivated rabies vaccine in addition to investigate the effect of such drugs on the levels of serum proteins.

SNT revealed that vaccination of puppies with the inactivated cell culture rabies vaccine resulted in induction of specific rabies neutralizing antibodies from the first week post vaccination in all puppy groups increased gradually to reach their peak by the 4th week later then still unchanged till the 12th month (table 1). It was visible that the highest levels of serum neutralizing rabies antibodies were determined in puppies received Levamisol® (256). Other treated puppy groups did not show significant differences between them and the vaccinated un-treated group (32) except the treated group with E-Mox® which showed the lowest antibody titer (15).

In addition, it was clear the results of ELISA were parallel to those of SNT showing that the highest levels of rabies ELISA antibodies were determined in puppies received Levamisol® (2.91). Other treated puppy groups did not show significant differences between them and the vaccinated un-treated (2.5) group and Yomesan® treated group (2.3) except the treated group with E-Mox® which showed the lowest antibody titer (1.5) as tabulated in table (2).

These results came to be parallel to and confirmed by the findings of [17];[18];[19];[20];[21] and [22] who stated that the cell culture inactivated rabies vaccine is safe for all animal species and clarified that the protective neutralizing antibody titer should not be less than 1:5.

Regarding the effect of the used drugs on the immune response of vaccinated puppies, it was stated that Levamisol® has an immune stimulant effect on treated vaccinated puppies where it was showed that Levamisol® fast the formation of protective levels of specific antibodies (23). It was

found that Levamisol® enhances the immune response to influenza vaccines [24] and it was mentioned that Levamisol® enhances specific and nonspecific immunity to *Corynebacterium* [25]. Also Levamisol® increased the antibody levels to many viral vaccines as demonstrated by [26];[27];[28];[29];[30];[31];[32]; and [33]. On the other side the low titer of rabies antibodies in puppies treated with E-Mox® could be attributed to its content of amoxicillin which has an immune suppressive effect in vaccinated animals where it was established that amoxicillin administration durably altered the gut microbiota of these animals [34]. They observed that the induction of the specific humeral response to ovalbumin was impaired when it occurred during antibiotic administration to the rat pups. Globally, these data suggest that antibiotic administration early in life negatively affects the specific immune response to a luminal antigen when it is first introduced during antibiotic administration.

Estimation of serum proteins showed that the highest levels of serum proteins were determined in puppies received Levamisol® (8.87 ± 0.25 ; 1.9 ± 0.07 & 6.7 ± 0.22 g/dl for total protein; albumin and globulin, respectively). Other treated puppy groups did not show significant differences between them and the vaccinated un-treated group and Yomesan® treated group (8.3 ± 0.55 ; 1.98 ± 0.07 & 6.32 ± 0.33 g/dl and 7.78 ± 0.14 ; 1.3 ± 1.1 & 5.9 ± 0.9 g/dl in untreated and puppies received Yomesan® for total protein; albumin and globulin, respectively) except the treated group with E-Mox® which showed the lowest levels (6.9 ± 1.1 ; 2.5 ± 0.04 & 4.4 ± 0.30 for total protein; albumin and globulin, respectively) while un-vaccinated un-treated puppies had 6.1 ± 0.15 ; 3.1 ± 0.32 & 2.5 ± 0.07 g/dl for total protein; albumin and globulin, respectively as tabulated in table (3). These findings were obtained by the 3rd week post vaccination. In general; the increased levels of total serum protein is attributed to the induced antibodies which

mainly composed of globulin coming in agreement with it was stated that serum proteins could be increased in animals after immunization [35]. It was reported that serum total protein; albumin and globulin were found to be 6.1-7.8gm/dl; 3.1-4.0gm/dl and 1.3-3.3gm/dl respectively in healthy dogs [36]. The albumin was found to be decreased due to inhibition of synthesis of albumin or an increase in globulin concentration. Alternation in globulin especially Gama globulin was usually a response of reticulo-endothelial system to antigenic stimulation (viral; bacterial or parasitic); it was found that low levels of serum albumin were accompanied with high levels of beta and Gama globulins which might be due to reduction in albumin synthesis in the liver[37]. It was stated that in dogs, the total serum protein, albumin and globulin were 5.7-7.7gm/dl; 2.5-4.0gm/dl and 3.2-3.7gm/dl respectively [38]. Total serum protein level was found to be increased with age increased with antigenic stimulation; it was showed that there was an increase in the levels of total serum protein due to the increased globulin in dogs vaccinated with rabies; canine distemper and canine parvovirus vaccines under normal conditions[39]. It was clearly noticed that high levels of serum proteins were determined in a parallel manner with high levels of induced rabies antibodies in vaccinated puppies treated with Levamesol®, with lower levels of serum proteins and antibodies in puppies treated with E-Mox® which suppressed puppy immune response.

5. REFERENCES

1. Drew, W. L. 2004. Rabies, Sherris Medical Microbiology (4th Ed.).McGraw Hill. pp. 597–600.
2. Cortan, R. S., Kumar, V., and Fausto, N. 2005. Robbins and Cotran Pathologic Basis of Disease (7th Ed.) St. Louis: Elsevier/Saunders pp. 1375.
3. Gough, P. M. and Jorgenson, R. D. 1976.Rabies Antibodies in Sera of Wild Birds. J. Wildlife Dis. Vol. 12 /12/3/392.
4. Pawan, April and December 1936.Transmission of the Paralytic Rabies in Trinidad of the Vampire Bat: *Desmodus rotundas murinus* Wagner, 1840". Annals of Tropical Medicine and Parasitology 30: 137–156. Rabies in the Vampire Bat of Trinidad with Special Reference to the Clinical Course and the Latency of Infection0.
5. Taylor, P. J. 1993. A systematic and population genetic approach to the rabies problem in the yellow mongoose (*Cynictispenicillata*). Onderstepoort J. Vet. Res. 60 (4): 379–87.
6. CDC (2010): Rabies Other Wild Animals: Terrestrial carnivores: raccoons skunks and foxes..
7. The Merck Manual, 11th Edition 1983. p. 183 and The Merck manual of Medical Information Second Home Edition, (2003), p. 484.
8. Turton, J. 2000. Rabies: a killer disease. National Department of Agriculture <http://www.nda.agric.za/docs/rabies/rabies.htm>.
9. WHO 2008. Rabies <http://www.who.int/mediacentre/factsheets/fs099/en/>.
10. Thomas, M. and Rivers, A. 1952. Viral and Rickettsial infections. J.B. LIPPI, N.Cott Comp.2nded.USA: 267-296.
11. El-Kanawati, Z. R., Ikram, A., Karim, Afaf, Amin; and El-Ebeedy, A. A. 2000. Occurrence of rabies in Egypt during 1997-1999 J. Egyp. Vet.Med. Ass. 60: 47-54.
12. Macpherson, L. A. and Stocker, M. G. P. 1962. Polyoma transformation of hamster cell colonies; An investigations of genetic factors affecting cell competence. Virology, 16: 147.
13. Lannette, E. H. 1964. Diagnostic procedures for viral and rickettsial diseases.
14. Bass,E. P., Gill, M. A., and Beckenhaur, W. H. (1982): Development of a modified live canine origin parvovirus vaccine. J.A.V.M.A. 181 (9): 909-913.
15. Hubschle, O. J., Lorenz, R. J., and Mathek, H. D. 1981. Enzyme linked immunosorbent assay for detection of blue tongue virus antigen. Am. J. Vet. Res., 42: 61-65.
16. Voller, A., Bidwell, D., and Bartlett, A. 1976. Enzyme immunosorbent assay for diagnosis of virus infection. Manual of clinical Microbial., Washington, D. C. Am. Soc. Microbiol.: 506-512.

17. Larghi, O. P. and Nebel, A. E. 1980. Rabies virus inactivation by Binary Ethylene mine: New method for inactivated vaccine production. *J. Clin. Microbiol.* 2: 120-122.
18. El-Karamany, R. M. 1986. Production in VERO cells of an inactivated rabies vaccine from strain FRV-K for animal and human use. *Acta.Virol.*, 31 (4): 321-328.
19. Sikes, R. K. and Larghi, O. P. 1971. Purified rabies vaccine: Development and comparison of potency and safety with two human rabies vaccines. *J. Immunol.*, 99 (3): 545-553.
20. Bass, E. P., Gill, M. A., and Beckenhaur, W. H. 1982. Development of a modified live canine origin parvovirus vaccine. *J.A.V.M.A.*, 181 (9): 909-913.
21. Khodier, M. H.; Khirat, A. Elian; Edries, S. M. and Gehan, K. M. 1998. Preparation of a combined inactivated vaccine against rabies and Rift Valley fever 4thSci.Vet.Med.Zag.Conf: 209-216.
22. Khodier, M. H. 1999. Studies on vaccination of farm animals (cattle, horse, sheep) in addition to dogs and cats with inactivated tissue culture rabies vaccine. *Beni-Suif Vet. Med. J.* 9 (3-A): 111-120.
23. Renoux, G. And Renoux, M. 1971. Stimulation of antibrucella vaccination in mice by tetramisol, a phenyl imidothiazole *Infect. Immun.*, 8: 544-548.
24. Brugmans, J., Schuermans, V., Van Nimmen, L., DeCock, W., Thienpont, D., Janssens, P., Verhaegen, H., Louwagie, A. C. and Steven, E. 1973. Restoration of host defense mechanism in man by levamisol *Life Sci.*, 13: 1499-1501.
25. Irwin, M. R. and Kinght, H. D. 1975. Enhanced resistance to corynebacterium pseudotuberculosis infection associated with reduced serum immunoglobulin levels *Infect.Immunol.* 12: 191-1103.
26. Synoens, J., Rosthol, M., De Brabander, M., and Golestein, G. 1979. Immune regulation with levamisol. *Springer Seminars in Immune Pathology*, 195-214.
27. Koller, A. and Jayappa, S. 1982. Chemicals induced immunomodulation *J. Am. Vet. Med. Ass.* 181 (10): 1102-1106.
28. Confer, A.W., Hall, S. M., and Espe, B. H. 1985. Transient enhancement of the serum antibody response to brucella abortus strain 19 in cattle treated with levamisol. *Vet. Rec.* 124 (8): 196-197.
29. McAnulty, J. F. and Rudd, R. G. 1985. Thrombocytopenia associated with vaccination of dogs with modified live vaccines *J.Am.Vet. Med. Assoc.*186 (11): 1217-1219.
30. Ivanov, I. E., Arsov, R., Simov, I., Dimov, I., and Sizov, I. 1987. Effect of tuberculin and levamisol on the immune response after vaccination of calves and salmonella infection. *Vet. Med. Nauki*, 24 (4): 43-49.
31. Polkova, S. M. and Shmeleva, E. A. 1990. The immunomodulating properties of a diphtheria bacterial vaccine in in-vitro experiment *Zh. Mikrobiol. Epidemiol. Immunol.*12:62-66.
32. Sharma, L. K., Jagadish, S. and Mulbagal, A. N. 1993. Effect of levamisol on delayed type hypersensitivity in cross bred calves. *Ind. Vet. J.* 70 (8): 699-701.
33. Hemmat, S. El-Emam 2002. Investigation on problems of vaccination of dogs against some infectious diseases *M. Vet. Sci. Thesis (Infectious Diseases) Faculty of Veterinary Medicine Alexandria University.*
34. Nutten, S., Schumann, A., Donnicola, D., Mercenier, A., Rami, S. and Garcia-Rodenas, C. L. 2007. Antibiotic Administration Early in Life Impairs Specific Humeral Responses to an Oral Antigen and Increases Intestinal Mast Cell Numbers and Mediator Concentration. *Clin.Vaccine Immunol.* 2007 February; 14 (2): 190-197.
35. French, N. H. 1936. The protein changes in serum induced by hyper immunization against rinderpest.
36. Coles, E. H. 1980. Plasma protein. *Vet. Clin. Path.*3rd Ed. 519-521.
37. Karasia, F. and Schefer, M. 1984. Diagnostic experiences with metabolic liver disease of dairy cows. *Vet. Bull.*, 54 (11): 962.
38. Bush, B. M. 1991. Total plasma protein, Interpretation of laboratory results for small animal clinicians, 238-253.
39. Hemmat S. El-Emam 2002. Investigation on problems of vaccination of dogs against some infectious diseases. *M. Vet. Sci. Thesis (Infectious Diseases) Faculty of Veterinary Medicine Alexandria University.*



استبيان تأثير بعض مضادات الطفيليات والمضادات الحيوية على الاستجابة المناعية للقاح السعار

محمد ابراهيم امام¹، السيد مصطفى ابراهيم²، عبد الفتاح منجد عبد الفتاح²، عبد المنعم محمد مصطفى² فيصل خليل حمودة² ومحمد حسن خضير³

¹اكاديمية الشرطة، ²كلية الطب البيطري - جامعة بنها، ³معهد بحوث الامصال واللقاحات البيطرية بالعباسية-القاهرة

الملخص العربي

لقد تم تصميم الدراسة الحالية لبحث تأثير بعض العقارات الشائع استخدامها في علاج الكلاب وتشمل المضادات الحيوية: مثل الایموکس ومضادات الطفيليات: مثل الليفاميزول واليوميزان على الاستجابة المناعية للكلاب للقاح السعار المصنع محليا بالإضافة لبحث تأثير تلك العقارات على مستوى البروتين في مصل الدم. وقد تم تتبع مستوى الاجسام المناعية للسعار في مصل الدم لكل الاجراء المقام عليها التجريبية باستخدام اختبار المصل المتعادل واختبار الانزيم المناعي المرتبط الغير مباشر اوضح اختبار المصل المتعادل ان تحصين الاجراء بلقاح السعار قد ادى الي ظهور اجسام مناعية من الاسبوع الاول للتحصين والتي تزايدت حتى وصلت لأعلي مستوي لها في الاسبوع الرابع وظلت كما هي حتى الشهر الثاني عشر. وقد لوحظ ان اعلي مستوي لتلك الاجسام قد ظهر في الاجراء التي تم علاجها بعقار الليفاميزول (265) بينما لم يلاحظ اختلاف بين تلك التي لم يتم علاجها (32) وتلك التي عولجت باليوميزان (32)، اما ما تم علاجه بعقار الایموکس فقد لوحظ فيه انخفاض لمستوي الاجسام المناعية في الجسم (16) عن تلك التي لم يتم علاجها باي عقار. وقد كانت النتائج الناتجة عن اختبار الانزيم المناعي المرتبط الغير مباشر موازيه لتلك التي تمت بطريقه اختبار المصل المتعادل ووضحت ان اعلي مستوى للاجسام المناعية قد ظهر في تلك المجموعة التي تم علاجها بعقار الليفاميزول (2.91)، بينما التي لم يتم علاجها (2.5) لم تظهر اختلاف عن المجموعة التي تم علاجها بعقار اليوميزان (2.3)، فيما اظهرت النتائج انخفاض نسبه الاجسام المناعية في المجموعة التي تم علاجها بالایموکس (1.5). بقياس مستوى البروتينات في مصل الدم لوحظ ارتفاع مستواه في المجاميع التي تم علاجها بالليفاميزول، بينما لم ترتفع في المجموعة التي تم علاجها بعقار اليوميزان وانخفض في المجموعة التي تم علاجها بعقار الایموکس.

(مجلة بنها للعلوم الطبية البيطرية: عدد 25(1): 165-172, سبتمبر 2013)